Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H20F3O3.Na |
| Molecular Weight | 460.4202 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC#C[C@@H](CC([O-])=O)C1=CC=C(OCC2=CC(=CC=C2)C3=CC=C(C=C3)C(F)(F)F)C=C1
InChI
InChIKey=CRTDAZVPDCRYKT-BOXHHOBZSA-M
InChI=1S/C26H21F3O3.Na/c1-2-4-21(16-25(30)31)20-9-13-24(14-10-20)32-17-18-5-3-6-22(15-18)19-7-11-23(12-8-19)26(27,28)29;/h3,5-15,21H,16-17H2,1H3,(H,30,31);/q;+1/p-1/t21-;/m0./s1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C26H20F3O3 |
| Molecular Weight | 437.4304 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24900872
https://www.ncbi.nlm.nih.gov/pubmed/22087278
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24900872
https://www.ncbi.nlm.nih.gov/pubmed/22087278
AMG-837 is an orally bioavailable partial agonist of the GPR40 (EC50 value 13.5 nM for AMG 837 stimulated Ca2 flux in CHO cells expressing human GPR40) with a superior pharmacokinetic profile. AMG837 stimulated robust glucose-dependent insulin secretion (EC50 value 142±20 nM) in isolated rodent islets, and lowered post-prandial glucose in normal rats. Acute administration of AMG-837 lowered glucose excursions and increased glucose stimulated insulin secretion during glucose tolerance tests in both normal and Zucker fatty rats. The improvement in glucose excursions persisted following daily dosing of AMG 837 for 21-days in Zucker fatty rats. Preclinical studies demonstrated that AMG-837 was a potent GPR40 partial agonist which lowered post-prandial glucose levels. AMG-837 exhibits a potential utility for the treatment of type 2 diabetes. Amgen removed AMG-837 from Phase I clinical trials due to concerns over toxicity.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. | 2011 Oct 13 |
|
| Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. | 2012 Nov |
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:45:49 GMT 2023
by
admin
on
Sat Dec 16 10:45:49 GMT 2023
|
| Record UNII |
T5KP187PIU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
865231-45-4
Created by
admin on Sat Dec 16 10:45:49 GMT 2023 , Edited by admin on Sat Dec 16 10:45:49 GMT 2023
|
PRIMARY | |||
|
46854654
Created by
admin on Sat Dec 16 10:45:49 GMT 2023 , Edited by admin on Sat Dec 16 10:45:49 GMT 2023
|
PRIMARY | |||
|
T5KP187PIU
Created by
admin on Sat Dec 16 10:45:49 GMT 2023 , Edited by admin on Sat Dec 16 10:45:49 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |